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Abstract
We report the first trial of candidate malaria vaccine antigen FMP1, a 42 kDa fragment from the C-terminus of merozoite surface
protein-1 (MSP-1) from the 3D7 strain of Plasmodium falciparum, in an endemic area. Forty adult male and female residents of west-
ern Kenya were enrolled to receive 3 doses of either FMP1/AS02A or Imovax® rabies vaccine by intra-deltoid injection on a 0, 1, 2
month schedule. Thirty-seven volunteers received all three immunizations and 38 completed the 12-month evaluation period. Slightly
more recipients of the FMP1/AS02A vaccine experienced any instance of pain at 24 h post-immunization than in the Imovax® group
DOI of original article:10.1016/j.vaccine.2005.11.028.
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(95% versus 65%), but otherwise the two vaccines were equally safe and well-tolerated. Baseline antibody levels were high in both groups and
were boosted in the FMP1/AS02A group. Longitudinal models revealed a highly significant difference between groups for both the average
post-baseline antibody responses to MSP-142 (F1,335 = 13.16; P < 0.001) and the Day 90 responses to MSP-142 (F1,335 = 16.69; P < 0.001). The
FMP1/AS02A vaccine is safe and immunogenic in adults and should progress to safety testing in children at greatest risk of malaria.
Published by Elsevier Ltd.
Keywords: Malaria; Vaccine; Merozoite surface protein; FMP1; AS02A; Randomized controlled trials
1. Introduction
Plasmodium falciparum, mankind’s ancient nemesis, kills
three children a minute [1]. Despite widespread efforts to
implement antimalarial drugs, bed nets and vector control, the
worldwide toll of malaria is undiminished [2]. Natural immu-
nity to malaria, acquired after multiple episodes of malaria,
does not prevent parasitemia, but does limit disease severity
and death [3,4]. A blood stage vaccine that accelerates the
acquisition of such immunity to P. falciparum malaria would
offer enormous benefit to the public health, particularly for
infants and children living in endemic areas who suffer the
most morbidity and mortality due to malaria [5].
The 42 kDa fragment of merozoite surface protein 1
(MSP-1) is a leading erythrocytic stage candidate antigen
for a malaria vaccine [6]. P. falciparum MSP-1 is a 195 kDa
protein that is proteolytically cleaved to yield four frag-
ments, one of which is the carboxy-terminal 42 kDa fragment
known as MSP-142 [7,8]. Further cleavage of the 42 kDa
fragment into 19 and 33 kDa fragments is important for
merozoite invasion [9]. Three lines of evidence support the
candidacy of MSP-142 kDa as a malaria vaccine. First, epi-
demiologic studies have demonstrated that antibody to the
19 kDa protein contained within MSP-142 is associated with
diminished P. falciparum disease severity [10,11]. Second,
antibodies raised in animals against MSP-142 or the 19 kDa
fragment inhibit the growth of P. falciparum in vitro [12].
Third, immunization of New World monkeys with recom-
binant MSP-1 formulated with a potent adjuvant confers
protection against blood stage challenge with P. falciparum
[13–15].
MSP-142 of the 3D7 clone of P. falciparum was cloned
and expressed in E. coli, purified and formulated accord-
ing to Good Manufacturing Practices (GMP). The final
product was named falciparum malaria protein 1 (FMP1)
[16]. Preclinical evaluation of FMP1 in the rhesus mon-
key safety and immunogenicity model identified AS02A
as a safe, well-tolerated, and highly immunogenic adjuvant
[17]. FMP1 formulated with GlaxoSmithKline’s proprietary
adjuvant AS02A proved safe and immunogenic in two previ-
ous trials conducted in 60 malaria naı¨ve volunteers in the
USA ([18] and Cumming’s unpublished data). The study
presented here, the first Phase 1 trial of FMP1/AS02A in
a malaria-experienced population, provides further safety
and immunogenicity data as part of a clinical development
plan that aims to develop vaccines to prevent disease in
children.
2. Materials and methods
2.1. Study design and population
This Phase 1 double-blind, randomized, controlled
trial evaluated the safety and immunogenicity of the
FMP1/AS02A candidate malaria vaccine versus Imovax®
Rabies in Kenyan adults. The primary objective was to assess
the safety and reactogenicity of the FMP1/AS02A vaccine in
malaria-experienced adults. The primary endpoints were the
occurrence of solicited signs and symptoms during an 8-day
period after each vaccination (day of vaccination and post-
vaccination days 1, 2, 3, and 7), occurrence of unsolicited
symptoms during a 30-day follow-up period after each vac-
cination, and the occurrence of serious adverse events (SAEs)
during the 1-year study period. The secondary objective was
to quantify the humoral immune response. The secondary
endpoint, the anti-FMP1 antibody titer, was determined by
enzyme-linked immunosorbent assay (ELISA) just prior to
and 14 days after each immunization and on days 90, 180,
272 and 364 after the first immunization.
The trial was carried out in Kombewa Division, western
Kenya. The area is part of the Lake Victoria basin where
most of the population belongs to the Luo ethnic group and
is engaged in subsistence fishing and farming. P. falciparum
in this region is holoendemic and transmission is intense,
principally via Anopheles gambiae mosquitoes [19]. Before
enrollment, volunteers gave a detailed medical history and
underwent a physical examination and laboratory evaluation
to determine if they had any underlying disease that might
confound their evaluation. Volunteers were eligible for enroll-
ment if they were 18–55 years of age, male or female, in
good health and agreed to participate for 12 months. Exclu-
sion criteria included any evidence of chronic illness or of
hematological, renal or hepatic pathology. Specific exclu-
sion criteria were as follows: prior receipt of an investiga-
tional malaria vaccine or rabies vaccine, recent or planned
use of any investigational drug, vaccine, immunoglobulin or
any blood product, use of immunosuppressant drugs, con-
firmed or suspected immunodeficiency, history of surgical
splenectomy, alcohol or drug abuse, pregnancy or concur-
rent participation in another clinical trial. Laboratory exclu-
sion criteria were serum alanine aminotransferase (ALT)
≥84 IU/L, serum creatinine ≥2.0 mg/dL, absolute lympho-
cyte count ≤1.0 × 103/L, a positive urine or plasma beta-
human chorionic gonadotropin (-HCG), or a hemoglobin
(Hgb) <10 g/dL for men or < 8 g/dL for women.
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2.2. Vaccines
The expression, purification, biochemical and immuno-
logical characterization of E. coli produced, GMP-
manufactured FMP1 antigen has been described [16]. The
adjuvant system AS02A consists of an oil-in-water emulsion
containing two immunostimulants, 3-deacylated monophos-
phoryl lipid A (MPL) (Corixa Inc., Seattle, WA) and QS21
(Antigenics Inc., Lexington, MA). The AS02A adjuvant
was manufactured by GlaxoSmithKline Biologicals (Rixen-
sart, Belgium) under GMP conditions and was provided in
prefilled syringes. Immediately prior to immunization, the
lyophilized FMP1 antigen was reconstituted in AS02A to
yield a milky white fluid containing a final dose of 50g
of FMP1 in a volume of 0.5 mL of AS02A. The compara-
tor vaccine, Imovax® Rabies, is an inactivated rabies vac-
cine produced by Aventis Pasteur, S.A., as a sterile, stable,
freeze-dried suspension of inactivated rabies virus prepared
from strain PM-1503-3M obtained from the Wistar Institute,
Philadelphia, PA. Immediately prior to immunization, the
rabies vaccine was reconstituted with sterile water for injec-
tion to yield a clear pink liquid. Each 1 mL dose contained
<100 mg of human albumin, <150g of neomycin sulfate,
20g of phenol red indicator and ≥2.5 IU of rabies antigen.
2.3. Immunizations and assessment of primary endpoints
Forty volunteers were randomized in a 1:1 ratio to receive
either FMP1/AS02A or Imovax® Rabies vaccine. Random-
ization was carried out in blocks of four with no stratification.
The only personnel at the study site with access to the ran-
domization list during the study were the study Drug Manager
and Pharmacist. The Medical Monitor also had one set of the
randomization codes in a sealed envelope in the event that
emergency unblinding was required. Volunteers were immu-
nized at 0, 1, and 2 months in the left deltoid muscle.
Because the color and volume of the reconstituted
FMP1/AS02A and Imovax® differed, blinding the individ-
uals responsible for preparing the vaccine was not possible.
However, individuals administering the vaccine and perform-
ing follow-up evaluations were blinded. The vaccine prepa-
ration area and the immunization area were physically and
visually separated. All vaccines were prepared by a desig-
nated Drug Manager and Pharmacist who were not involved
in vaccine administration or follow-up of volunteers. Follow-
ing reconstitution of the vaccine the dose was drawn into a
1 mL tuberculin syringe and the barrel of the syringe was cov-
ered with opaque tape to mask its contents and labeled with
the volunteer ID and randomization code. The vaccine was
then handed to the immunization clinician who proceeded
with administration. Following immunization, the volunteer
was assessed by a separate group of clinicians who performed
all the follow-up assessments.
After each vaccination, volunteers were followed for 8
days (day of vaccination and post-vaccination days 1, 2, 3,
and 7) for solicited symptoms, 30 days for unsolicited AEs,
and until resolution of any SAE or pregnancy. The injection
site was assessed for pain, swelling, erythema, and limitation
of arm motion at the shoulder. Solicited general symptoms
were: fever, nausea, headache, malaise, myalgia and joint
pain. Pain was graded as follows: 0, absent; 1, painful to
touch; 2, painful with limb movement; and 3, spontaneously
painful. Swelling or erythema at the injection site was mea-
sured at the longest axis of involvement and graded as 0 if
absent, 1 if ≥1 but ≤20 mm, 2 if >20 but ≤50 mm, and 3 if
>50 mm. Limitation of arm motion was based upon the vol-
unteer’s active range of abduction; 0 if normal, 1 if >90 but
≤120◦, 2 if >30 but ≤90◦, and 3 if ≤30◦. All other symp-
toms were graded according to the extent of interference with
daily activity; 0, none; 1, easily tolerated; 2, interferes with
daily activity; and 3, prevents daily activity. After the third
administration of vaccine, volunteers were followed monthly
by field workers at home and were asked to return to the clinic
every 3 months until the end of the study for safety follow-up.
SAEs were collected and reported throughout the 12-month
period of the study. An SAE was defined as an event that was
life threatening, or resulted in or prolonged hospitalization, or
resulted in persistent or significant disability, or a congenital
anomaly in the offspring of a vaccinated female. Serum crea-
tinine, ALT, white blood cell count, platelet count, Hgb, and
hematocrit were determined on days 0, 14, 30, 44, 60, 74, and
90. Additional Hgb determinations were made on days 180,
272 and 364. Normal ranges were calculated based upon the
local population. -HCG was determined within 48 h before
each immunization.
2.4. Measurement of humoral responses
Immune response to the FMP1/AS02A vaccine was deter-
mined by anti-MSP-142 ELISA endpoint titers. For the
ELISA, the MSP-142 capture antigen was diluted in anti-
gen diluent (pH 7.4 phosphate buffered saline (PBS), 0.5%
boiled casein) to a concentration of 0.5g/mL. Wells of
96-well plates were coated with 100L of diluted antigen
overnight at 4 ◦C, and blocked with a solution of 0.5% boiled
casein in PBS. All subsequent steps were carried out at room
temperature. Sera were serially diluted in triplicate on the
plates from 1:500 to 1:64,000 and incubated for 2 h, followed
by horseradish peroxidase-conjugated goat anti-human IgG
(KPL, Gaithersburg, MD) diluted 1:1000 in PBS diluent, for
1 h. After addition of 2,2′-azino-bis(3-ethylbenzthiazoline-6-
sulfonate) (ABTS) peroxidase substrate (Kirkegaard & Perry
Laboratories Inc. Gaithersburg, MD), plates were incubated
for 1 h, and the reaction stopped by addition of 10L of
20% SDS (Sigma, St. Louis, MO) stop solution. Plates were
washed between all steps with an automated plate washer
(Molecular Devices, Sunnyvale, CA) using four rinses of
PBS with 0.05% Tween 20 (Sigma). Plates were then read
by an automated plate reader (Vmax Molecular DevicesTM)
at 414 nm, and the serial dilutions used to fit a 4-parameter
curve using SoftMax Pro v4.1 (Molecular Devices). Results
were expressed in titer values, the titer endpoint being defined
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as the calculated serum dilution yielding an optical density
of 1.0 in our assay. Two positive controls, one negative con-
trol, and blank wells were included on every plate for quality
assurance. Plates not meeting pre-defined limits for control
values were excluded and the samples re-tested.
Fine specificity of antibody responses was assessed using
recombinant fragments of MSP-142 including MSP-119,
endodermal growth factor (EGF) domains 1 and 2 from the
3D7 allele of P. falciparum. The individual fragments from
MSP-142 were expressed as GST-fusion proteins in E. coli
and purified to >95% purity [15]. Microtiter plate (Immulon-
2 HB; Thermo Labsystems, Franklin, MA) wells were coated
with 0.8 pmol of recombinant antigen in 100L of PBS and
incubated overnight at 4 ◦C followed by blocking for 1 hr at
room temperature with 300L of blocking buffer (1% Frac-
tion V BSA in PBS). Sera were diluted serially with blocking
buffer and incubated for 2 h at room temperature. Plates were
washed 4 times with wash buffer (0.05% Tween 20, 0.0025%
Chlorohexidine in PBS) using a microplate washer (Skan-
Washer 300 version B, Skatron Instruments, Sterling, VA).
Goat anti-human IgG (H + L)-alkaline phosphatase conju-
gate diluted to 1:1000 (Promega, Madison, WI) was added
to each well and incubated at room temperature for 1 h. P-
Nitrophenyl phosphate substrate (Sigma, St. Louis, MO) was
added to each well and the OD405nm was measured after
60 min with a microplate reader (Molecular Devices, Spectra-
Max Plus 384, SoftMax Pro software). The antibody titer was
calculated in the same way as the endpoint titer above. For the
analyses comparing MSP-142 fragment-specific Ab titers, the
plate antigens were normalized to one another. Equal molar
coatings (0.8 pmol/well) for each ELISA plate antigen were
confirmed by detecting with antibody against the GST moiety
of the fusion protein (in the case of p19, EGF1, and EGF2),
or mAb 5.2 (in the case of MSP-142 and p19).
2.5. Data safety monitoring board and regulatory affairs
An independent Data Safety Monitoring Board (DSMB)
was appointed prior to the study start to review safety data
during and after the course of this trial. DSMB membership
included a statistician and four senior clinical investigators
with experience in conducting malaria vaccine trials. The trial
was monitored for regulatory compliance by representatives
from the United States Army Medical Materiel Development
Activity, GlaxoSmithKline Biologicals, and Pharmaceuticals
Product Development, a contract research organization based
in Wilmington, NC.
2.6. Data handling and statistical analyses
Analyses and descriptive tables of the final database were
made using SAS version 8.2 (SAS Institute, Cary, NC).
Comparisons of the proportion of volunteers by group expe-
riencing any symptom or event were made by Fisher’s exact
test without correction for multiple comparisons. Compar-
isons of serologic responses by group were made using
geometric mean endpoint dilution titers. Confidence inter-
vals for serologic responses were calculated by transforming
individual data to base 10 logarithms, calculating the 95%
confidence interval based upon the normal distribution, and
then exponentiating the confidence limits. For volunteers who
received all scheduled immunizations, group responses were
compared using a longitudinal model, with a spatial power
covariance structure (SAS, version 8.2), to assess the effect of
vaccination on the mean level of antibody over time. A one-
sided t-test (alternative hypothesis: FMP1 slope > Imovax®
slope) was performed to determine if the two groups differed
in the rate of antibody development between days 0 and 90.
3. Results
3.1. Study conduct and participant flow
The study was conducted from April 2002 to April 2003.
A total of 199 people were briefed; of these 139 consented
to screening. Of the 107 who returned for screening, 40
(14 females and 26 males) were enrolled and randomized
to one of two treatment groups. The groups were compara-
ble in baseline demography, clinical laboratory values and
distribution of antibody to FMP1 (Table 1). All 40 partic-
ipants received the first two immunizations. Three did not
receive the third immunization but were followed as per pro-
tocol. Subject FMP1–1–032, who received Imovax®, was
excluded from the third dose because of transient transami-
Table 1
Clinical and demographic baseline characteristics of enrolled volunteers
Characteristics Imovax® N = 20 FMP1/AS02A N = 20
Mean age in years (S.D.) 32.9 (11.4) 33.7 (9.6)
No. male 13 13
Mean WBC × 103/L (S.D.) 6.0 (2.2) 5.1(1.4)
Mean hemoglobin g/dL (S.D.) 12.9 (1.7) 13.5 (2.1)
Mean platelets × 103/L (S.D.) 224 (67) 214 (68)
Mean lymphocyte count × 103/L (S.D.) 2.3 (0.5) 2.2 (0.8)
Mean creatinine mg/dL (S.D.) 0.76 (0.15) 0.78 (0.15)
Mean ALT U/L (S.D.) 20.5 (14.0) 15.0 (4.7)
GMT anti-MSP-142 antibody titer (95% CI) × 103 24 (12–47) 18 (9–38)
GMT: geometric mean titer; CI: confidence interval; ALT: alanine amino-transferase.
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Fig. 1. CONSORT diagram summarizing the number of volunteers at each stage of the trial.
nase elevation. Subject FMP1-1-004 (Imovax®) missed the
third immunization because of visit noncompliance, and sub-
ject FMP1-1-083 (FMP1/AS02A) was excluded because he
left the study area (Fig. 1).
3.2. Safety and reactogenicity
The vaccines were well tolerated. No withdrawal due
to vaccine side effects occurred. Table 2 summarizes the
solicited signs and symptoms. The most common side effect
related to immunization was pain at the site of injection. In
general, more FMP1/AS02A vaccinees reported pain at the
injection site within 24 h than did Imovax® vaccinees. The
pain was more prominent with the first injection than with
subsequent doses. In most cases the pain resolved within
48 h. There were no other differences in solicited symptoms
during the 8-day follow-up periods in vaccine-related signs
and symptoms. There was no difference in the occurrence of
Grade 3 local events between the FMP1/AS02A and Imovax®
recipients by dose or by group. After three immunizations,
8 of 20 individuals in the Imovax® group and 9 of 20 in the
FMP1/AS02A group experienced at least one Grade 3 local
reaction. No Grade 3 solicited systemic reaction occurred
in either group during the 8-day follow-up period. Three
Grade 3 unsolicited AEs occurred during the three 30-day
post-immunization follow-up periods, but none was causally
related to immunization. In the Imovax® group, one volunteer
experienced gastroenteritis and another experienced enteritis;
Table 2
Number of volunteers who experienced solicited signs and symptoms during the 8-day follow-up after each immunization
Imovax® FMP1/AS02A
Dose 1 N = 20 Dose 2 N = 20 Dose 3 N = 18 Dose 1 N = 20 Dose 2 N = 20 Dose 3 N = 19
Local
Pain 10 11 10 17* 11 13
Arm motion limitation 2 0 2 4 0 3
Swelling 0 0 2 0 2 5
Erythema 0 0 0 0 0 0
Systemic
Fever 1 1 0 1 0 0
Headache 4 4 1 6 5 4
Arthralgia 1 2 0 0 3 1
Myalgia 3 2 0 1 1 1
Malaise 4 2 0 1 2 3
Nausea 0 0 0 0 3 0
* P value = 0.04 compared to Imovax® Dose 1.
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Fig. 2. Group mean hemoglobin levels over time. Error bars represent point
wise 95% confidence interval of the mean.
in the FMP1/AS02A group, one volunteer injured his left
knee.
Ten documented SAEs occurred in nine volunteers during
the study; 7 in seven volunteers in the Imovax® group and 3 in
two volunteers who received FMP1/AS02A. In the Imovax®
group, three volunteers contracted malaria, two developed
sepsis, one experienced a ruptured ectopic pregnancy, and one
experienced gastroenteritis. In the FMP1/AS02A group, one
volunteer contracted malaria, and another experienced two
separate SAEs: gastroenteritis (possibly typhoid fever) and
pneumonia. No SAE was deemed causally related to immu-
nization.
In addition, volunteer FMP1-1-097, who received the
FMP1/AS02A vaccine, presented on day 364, the last sched-
uled study visit, with symptoms of fatigue and history of
heavy menstruation. She was pale and had a hemoglobin level
of 5.3 g/dL. A Giemsa-stained thick and thin smear revealed
no evidence of malaria. A stool sample showed evidence
of hookworm infection. She was treated with mebendazole,
folate, and iron supplementation and recovered uneventfully.
Group mean and group median safety laboratory values
(WBC, Hgb, Hct, Plt, Cr and ALT) were unchanged in the
30-day post immunization follow-up period. Likewise, lon-
gitudinal models of the extended Day 90–Day 364 determi-
nations of Hgb showed no change for group mean or median
values (data not shown). Group mean Hgb values and point
wise 95% CI are depicted for the 12-month period of follow
up (Fig. 2).
3.3. Immunogenicity
The volunteers had high pre-existing antibody titers to
FMP1 prior to immunization. The baseline GMT (in thou-
sands) for FMP1/AS02A vaccinees who received all three
immunizations was 17 (point wise 95% CI: 8–36) and
for Imovax® vaccines 26 (point wise 95% CI: 13–51).
Among FMP1/AS02A vaccinees, anti-FMP1 titers increased
after each dose, peaking on day 90 at 46 (point wise
Fig. 3. Group geometric mean anti-MSP-142 titers.
95% CI: 28–77) versus Imovax® 25 (point wise 95% CI:
12–51), and remained higher than Imovax® vaccinees on
day 364. Among Imovax® vaccinees, anti-FMP1 titers were
relatively constant throughout (Fig. 3). Log10-transformed
titer data were analyzed using longitudinal mixed mod-
els. These models account for correlations within volun-
teers, thus producing more precise estimates at each time
point than point wise comparisons. Therefore, even though
point wise comparisons do not show statistically significant
differences, longitudinal models revealed a highly signifi-
cant difference between groups for both the average post-
baseline responses (F1,335 = 13.16; P < 0.001) and the Day
90 responses (F1,335 = 16.69; P < 0.001). Comparison of the
anti-MSP-142 antibody titers at 0 and 90 days illustrates
that among FMP1/AS02A vaccinees both low and high pre-
existing titers were boosted in this semi-immune adult pop-
ulation (Fig. 4).
Proteolytic cleavage of MSP-142 into fragments MSP-
133 and MSP-119, the latter containing two EGF domains,
is felt to be important for invasion [9]. Therefore, in order
to determine if immunization with FMP1/AS02A was able
to induce more anti-MSP-142, anti-MSP-119, anti-EGF-1
or anti-EGF-2 antibodies, we measured immune responses
against recombinant antigens of these peptides. Consistent
with the antibody titers against MSP-142 (Fig. 3), at the spec-
ified time points we observed no significant differences in
mean endpoint titers against these peptides between the two
groups. We felt the most likely explanation for this was the
high malaria transmission intensity in the study site, which in
semi-immune adult volunteers may have overshadowed the
inductive (recall) capacity of the vaccine. In order to minimize
the effect of fluctuations in antibody titers due to intermittent
infections, we reanalyzed the antibody titers as a function
of time. Table 3 presents the rate of antibody acquisition
between day 0 and 2 weeks and 4 weeks post third immuniza-
tion (Day 74 and 90) that were analyzed by ELISA against
fragments of MSP-142 3D7 (MSP-142, MSP-119, EGF-1 and
EGF-2). The results show that for the MSP-142, MSP-119,
and EGF-1 fragments, there are significant differences in the
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Table 3
Mean slope of the ELISA Ab response (ELISA Ab titer/day) of the regres-
sion line for days 0, 74, and 90
Plate Ag Imovax® N = 18
slope (S.E.)
FMP1 N = 19
slope (S.E.)
One sided
P-value
MSP-142 39(46) 178(61) 0.04
MSP-119 −43(43) 121(30) <0.01
EGF-1 18(16) 87(20) <0.01
EGF-2 42(13) 61(22) 0.23
S.E.: standard error of the mean.
rates of anti-MSP-1 fragment antibody development between
Imovax® and FMP1/AS02A groups (P = 0.04, <0.01, and
<0.01, respectively). No significant difference was observed
when sera were analyzed against the C-terminal most EGF-2
domain fragment of MSP-142. This interesting observation,
in light of the apparent prevalence of the FUP/Camp parasite
strain in this study area in Kenya, suggests that vaccina-
tion with FMP1/AS02A failed to recall an immune response
against EGF-2. One possible explanation is the lack of homol-
ogy between the vaccine strain and the local FUP/Camp
strain, even though their EGF-2 domains differ at only three
amino acid positions [12,20].
4. Discussion
This Phase 1 trial provided clear evidence of the safety
and tolerability of FMP1/AS02A when given to adults sub-
ject to intense malaria transmission in western Kenya. With
the exception of localized pain at the injection site at 24 h,
detailed post-immunization follow-up revealed that volun-
teers receiving FMP1/AS02A reported a similar incidence
and intensity of local side effects and general symptoms
compared to those receiving the licensed comparator rabies
vaccine. No local or systemic allergic event occurred. Of
the 10 SAEs occurring during this 12-month study, three
occurred in two volunteers who received FMP1/AS02A, but
neither the Principal Investigator, the Medical Monitor, nor
the Data Safety Monitoring Board found any causal relation-
ship with receipt of the vaccine.
With the ultimate goal of administering a malaria vac-
cine as part of the Expanded Program on Immunization
(EPI) to infants at greatest risk of malaria, we have tested
the FMP1/AS02A vaccine on an EPI-compatible 0-, 1- and
2-month schedule. This brisk schedule proved to be well
tolerated and was not associated with any new or higher
incidence of AEs than had been observed in initial trials of
FMP1/AS02A given on a 0-, 1-, and 3-month schedule in
healthy malaria-naı¨ve adults ([18] and Cumming’s unpub-
lished data).
There was a statistically significant antibody response
to a 3-dose regimen of FMP1/AS02A in a population with
substantial baseline antibody to this immunogen and rela-
tive clinical immunity to malaria. This immunogenicity of
the vaccine may have been lessened by the high levels of
pre-existent antibody titers in this semi-immune population
as suggested by the fact that the greatest rise in antibody
responses was seen in individuals with low pre-existing anti-
body levels (Fig. 4). By the same token, we did not observe
differences in endpoint titers against MSP-142 sub-fragments
but we demonstrated a higher rate of antibody develop-
ment against these peptides in FMP1/AS02A recipients. The
FMP1/AS02A vaccine was highly immunogenic in the ini-
tial trials conducted in malaria-naı¨ve adults in the USA ([18]
and Cumming’s unpublished data). These data suggest that
this vaccine will induce an even greater fold increase in anti-
FMP1 titers when evaluated in children with lower baseline
antibody titers. An efficacy trial will be required to establish
the relationship of antibody to FMP1 or to its subdomains
and clinical immunity to malaria.
Malaria is a well-described cause of anemia in areas of
intense transmission, particularly in infants and young chil-
dren with minimal immunity to clinical disease. Malarial
anemia is multifactorial in origin; it results from the combined
Fig. 4. Changes in anti-MSP-142 geometric mean OD units from Day 0 to Day 90.
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effects of suppression of erythropoiesis, lysis of infected
erythrocytes, and the accelerated destruction of uninfected
erythrocytes [21,22]. Although there are no validated predic-
tive models of human falciparum malaria [23], the observa-
tion of malaria-associated anemia in New World monkeys
with prolonged Plasmodium falciparum parasitemia has led
to speculation that malaria vaccines eliciting immunity that
controls but does not eliminate parasitemia might them-
selves increase the risk of anemia in endemic populations
[24]. Hemoglobin levels were stable in both groups for 365
days, suggesting that FMP1/AS02A had no adverse group
effect on hemoglobin levels following immunization and
exposure to malaria. A single instance of significant ane-
mia not associated with concurrent malaria was noted on
Day 364 in FMP1/AS02A-immunized volunteer FMP1-1-
097, who had a history of menorrhagia and severe hookworm
infection, and responded to iron, folate, and antihelminthic
treatment.
The clinical development plan for FMP1/AS02A has two
immediate goals: an expansion of the safety and immuno-
genicity profile in endemic populations, followed by determi-
nation of the preliminary efficacy of this vaccine for reduction
of clinical malaria in children at risk of disease. Later in
2003, the DSMB, on the basis of the results presented here,
endorsed a Phase 1 trial of FMP1/AS02A in children. Accord-
ingly, we then conducted a Phase 1b dose-escalation trial of
FMP1/AS02A in 135 Kenyan children 1–4 years of age that
enabled selection of a safe, well-tolerated, immunogenic dose
of FMP1/AS02A for an efficacy trial that began in April 2005.
The results of these trials will be reported in future commu-
nications.
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